Dr
Simon
Turberville

Patent Director

London Office

Telephone. +44(0) 207 776 5100
Mobile. +44(0) 758 461 0797
Email. [email protected]

Experience

Simon began his patent career in private practice before joining the in-house department of a FTSE 100 multinational chemical company in 2012. As an in-house attorney, Simon was responsible for the patent portfolios of a contentious product area in the automotive catalysts sector. He has considerable experience in handling oppositions and appeals at the European Patent Office, and providing advice on patent validity and freedom-to-operate.

Simon returned to private practice in 2018 when he joined the London office of HGF. He draws on both his private practice and in-house experience to provide commercially-focused advice to his clients in relation to all patent matters.

Specialisms

  • Catalysis
  • Energy
  • Material science
  • Pharmaceutical technologies
  • Polymer chemistry
  • Printing technologies

Industries

  • Automotive icon Automotive
  • CleanTech icon CleanTech
  • Medical devices icon Medical devices
  • Pharmaceuticals icon Pharmaceuticals

Services

  • Due diligence
  • In-house legal support
  • Patent oppositions & appeals
  • Patents
  • Portfolio management
  • Searching & competitor monitoring
  • Strategy

Qualifications

Patent Attorney

Chartered (UK)
European


MCHEM

1st class, Oxford University

OTHER

DPhil, Organometallic Chemistry, Oxford University

CSR

Simon is a mentor for Oxford University’s Crankstart Careers Mentoring Programme.

Related News

EPO Enlarged Board of Appeal decision G4/19 - a European patent application can be refused by reason of the prohibition on double patenting

The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’.  Such a refusal can …

Read article

Managing Intellectual Property IP Stars & Firm Rankings 2021

Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …

Read article

Medical technology most patented subject matter at EPO in 2020

Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …

Read article

The EPO ‘How To’ guide for antibody applications in Europe

The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …

Read article

Personalised drug patenting in Europe

Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …

Read article

The Internet of Medical Things

Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …

Read article

Covid-19 vaccine patent waivers

To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …

Read article

G1/21 hearing at the EPO

Follow this page for the updates from G1/21 hearing at the EPO on 28th May 2021. HGF Partners Dr Chris Moore and Douglas Drysdale will be reporting all the key …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.